Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1988-9-21
|
| pubmed:abstractText |
Therapy of chronic graft-v-host disease (GVHD) has been unsatisfactory in patients with platelet counts less than 100,000/microL. Survival at 5 years after marrow transplant is only 26% in such patients treated with trimethoprim-sulfamethoxazole (TMP-SMX) and every other day with prednisone. Since October 1982, 61 patients with high-risk extensive chronic GVHD were treated with a new alternating-day regimen of prednisone (1 mg/kg every other day) and oral cyclosporine (6 mg/kg every 12 hours every other day) with one double-strength TMP-SMX tablet twice daily. Forty patients (group I) received primary treatment of thrombocytopenic chronic GVHD (median platelet count 35 [range 7 to 87] x 10(3)/microL). Twenty-one patients (group II) received salvage treatment after failing initial prednisone +/- azathioprine. Twenty-one patients in group I and 15 in group II survive with a minimum of 2 years and a median of 3.7 years follow-up. At 4 years after transplant, actuarial survival is 51% (group I) and 67% (group II). Causes of death included interstitial pneumonia (six), relapse (five), GVHD without infection (five), infection (four), organ failure (three), and hemorrhage (two). Mortality increased with the progressive type onset of chronic GVHD and treatment failure. Toxicity included hypertension (13), nephrotoxicity (nine), nausea (seven), aseptic necrosis (five), neurologic abnormalities (four), and diabetes (three). Median cyclosporine levels at four and 36 hours were 296 and 64 ng/mL, respectively. Four patients required permanent discontinuation of cyclosporine, but none required renal dialysis. Karnofsky performance scores for 25 survivors are 90% to 100%, scores for six survivors are 70% to 89%, and scores for five survivors are less than 70%. Alternating-day cyclosporine and prednisone has acceptable toxicity and appears to improve survival in patients with high-risk chronic GVHD.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
72
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
555-61
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:3042042-Adolescent,
pubmed-meshheading:3042042-Adult,
pubmed-meshheading:3042042-Bone Marrow Transplantation,
pubmed-meshheading:3042042-Child,
pubmed-meshheading:3042042-Child, Preschool,
pubmed-meshheading:3042042-Chronic Disease,
pubmed-meshheading:3042042-Cyclosporins,
pubmed-meshheading:3042042-Drug Administration Schedule,
pubmed-meshheading:3042042-Drug Therapy, Combination,
pubmed-meshheading:3042042-Female,
pubmed-meshheading:3042042-Graft vs Host Disease,
pubmed-meshheading:3042042-Humans,
pubmed-meshheading:3042042-Infant,
pubmed-meshheading:3042042-Infection,
pubmed-meshheading:3042042-Male,
pubmed-meshheading:3042042-Middle Aged,
pubmed-meshheading:3042042-Prednisone,
pubmed-meshheading:3042042-Thrombocytopenia
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
|
| pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Department of Medicine, Seattle, WA 98104.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|